Data continue to align with the CDC's RSV-Net surveillance1,2 of RSV-associated hospitalizations, which also showed a net increase during the same two week period.
The new data are from Wave 2 of a real-time tracking report on RSV released by InCrowd, a global pioneer of real-time, automated insights for the life science industry and an Apollo Intelligence (Apollo) brand.
Responding through InCrowd's mobile-integrated survey platform, validated physicians from the company's proprietary global panel were able to complete this research and share their frontline, real-world experiences in under 90 minutes.
Both severity and caseloads also increased in Wave 2 of the report as sourced by InCrowd's MicroTracker, real-time, automated tracking platform.
Sixty percent of doctors say the RSV cases they are treating are more severe than in previous years--a figure that also increased from 45% two weeks ago.
Doctors treated an average of 18 patients for RSV in the Wave 2 report, up from an average of 11 patients in Wave 1.
Forty-four percent of respondents in Wave 2 characterize the increase in RSV case numbers over the previous two weeks as very strong compared to 30% in Wave 1.
Wave 2 of the InCrowd RSV Tracker fielded Monday, November 7, 2022, in 90 minutes, and includes insights from n=100 ER and critical care doctors in the US, among them 62% who are based at community hospitals and 38% at academic hospitals.
Wave 1 of the InCrowd RSV Tracker fielded Monday, October 24th, 2022, in under five hours, with insights from n=103 ER and critical care doctors in the US, including 71% who are based at community hospitals and 29% at academic hospitals.
Data in both reports were obtained using a 1-minute MicroSurvey performed on InCrowd's agile, global market insights platform.
InCrowd's real-time tracking data on RSV is a complement to InCrowd Essentials syndicated research on the RSV market, a packaged solution that can help life science firms gauge awareness and opportunity in the evolving RSV therapeutic market.
In 2019, Apollo launched with the acquisition of InCrowd, a pioneer of real-time, automated insights for the life science industry.
To complement InCrowd and strengthen its global reach, in 2020, Apollo acquired Survey Healthcare Global, a global market leader of first-party healthcare data collection and custom survey solutions.
Apollo provides access to 2m healthcare stakeholders worldwide--including physicians, patients, caregivers, and allied healthcare professionals.
Apollo's 250+ employees support global pharmaceutical brands, market research agencies, and consultancies across 13 different countries in the Americas, Europe, and Asia. Apollo is a portfolio company of Frazier Healthcare Partners.
Opsidio doses first subject in OpSCF Phase 2a clinical trial
OncoResponse commences first subject dosing in OR502 Phase one/two trial
Photocure's partner Asieris Pharmaceuticals advances Hexvix NDA in China
Eli Lilly to open Lilly Gateway Labs in San Diego in H1 2024
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
MedGenome names new Advisory Board chairman
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Fusion Antibodies signs OptiMAL collaboration agreement with US National Cancer Institute
GeNeuro completes recruitment for long-COVID trial, anticipates top-line results by June 2024